About Arrakis Therapeutics
Arrakis Therapeutics is a Healthcare company based in Waltham (United States) founded in 2015 by Raj Parekh. Provider of tools for the analysis of RNA structures. Arrakis Therapeutics has raised $113 million across 2 funding rounds from investors including Pfizer, ARE and WuXi AppTec. The company has 91 employees. Its focus areas include Life Sciences, Genomics, Diversified and Oncology. Its legal entity is ARRAKIS THERAPEUTICS, INC. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Arrakis Therapeutics was founded in 2015 in Waltham, United States, within the biotechnology sector. Tools for RNA structure analysis are offered through bioinformatics platforms. These enable identification of RNA targets, design of drug molecules, and selection of therapeutic candidates. Novel drugs are under development for conditions including cancer, central nervous system diseases, and rare genetic disorders, with operations focused on advancing RNA-targeted therapies.
- Headquarters Waltham, United States
- Employees 91
- Founders Raj Parekh
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website arrakistx.com
- Social LinkedIn X Threads
- Legal Name Arrakis Therapeutics, Inc
- Total Equity Funding$113M (USD)
in 2 rounds
- Latest Funding Round$75M (USD), Series B
Apr 2019
- InvestorsPfizer
& 12 more
- Employee Count91
Funding Insights of Arrakis Therapeutics
Arrakis Therapeutics has successfully raised a total of $113M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $113M
- Total Rounds 2
- Last Round Series B — $75M
- First Round $38M
(Feb 2017)
- Investors Count 13
All 2 funding rounds of Arrakis Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $75M | Series B | – | VenBio, Nextech Invest | |
| Feb 2017 | $38M | Series A | – | Canaan |
13 investors in total: 12 institutional and 1 angel.
Investors in Arrakis Therapeutics
Arrakis Therapeutics has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Pfizer, ARE and WuXi AppTec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for Arrakis Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arrakis Therapeutics
43 people are tracked at Arrakis Therapeutics (18 in leadership, 25 in team); the tracked headcount is 91.
| Name | Role | Group |
|---|---|---|
Raj Parekh | Co-Founder | Leadership |
Emily Garcia Sega, Ph.D. | Associate Director | Leadership |
Sarah Mahoney | Associate Director, Discovery Biology | Leadership |
James Mutamba | Chief Business Officer | Leadership |
Jennifer C. Petter | Founder & Chief Scientific Officer | Leadership |
Alec Sexton | Associate Director | Leadership |
Michael Gilman | Chief Executive Officer | Leadership |
Anton Filikov | Associate Director/principal Scientist, Computational Drug Discovery | Leadership |
Andrea Crotti | Associate Director | Leadership |
Aaron Frank | Director and Head of Computational Chemistry | Leadership |
Craig Blain | Vp, Biology | Leadership |
Joerg Ruschel | Director - Program Management | Leadership |
Luis Soares | Director - Head Of Computational Biology | Leadership |
Anna A. (Zabierek) Mathias | Scientist, Compound Management Function Head | Leadership |
Domi Stickens | Chief Scientific Officer | Leadership |
Nabanita De | Associate Director, RNA Biochemistry | Leadership |
Elena Menichelli | Director, Head of Structural Biology | Leadership |
Herschel Mukherjee | Director | Leadership |
Elias Ndaru, Ph.D. | Scientist I (Medicinal Chemistry) | Team |
Hunter Linton | Senior Research Associate | Team |
23 more people are available in the full profile.
Complete people profiles for Arrakis Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Arrakis Therapeutics
3 dated milestones of Arrakis Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Arrakis Therapeutics is founded.
- Funding First funding round of $38.0M.
- Funding Latest funding round, Series B, of $75.0M.
Competitors of Arrakis Therapeutics
Arrakis Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Arrakis Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arrakis Therapeutics
The website of Arrakis Therapeutics (arrakistx.com) receives about 4.7K visits a month and ranks #3,693,300 among all websites worldwide, #4,739 in Biotechnology and Pharmaceuticals.
- Monthly visits4.7K
▼ 11.1% vs previous month
- Unique visitors2.3K
per month
- Global rank#3,693,300
among all websites
- Category rank#4,739
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.6
- Average visit9 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Arrakis Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| drugdiscoveryonline.com | 100% | #3,490,219 | View details | ||
wuxibiology.com | wuxibiology.com | 94% | #1,329,952 | – | |
| kisacoresearch.com | 86% | 26.4K | #1,034,436 | View details | |
aionlabs.com | aionlabs.com | 62% | #3,030,567 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Arrakis Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arrakis Therapeutics
Complete news archive for Arrakis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arrakis Therapeutics
Arrakis Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Arrakis Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Arrakis Therapeutics is a funded company, having raised a total of $113M across 2 funding rounds to date. The company's 1st funding round was a Series A of $38M, raised on Feb 2017.
Arrakis Therapeutics has 91 employees.
Arrakis Therapeutics was founded in 2015 in Waltham, United States, within the biotechnology sector. Tools for RNA structure analysis are offered through bioinformatics platforms. These enable identification of RNA targets, design of drug molecules, and selection of therapeutic candidates. Novel drugs are under development for conditions including cancer, central nervous system diseases, and rare genetic disorders, with operations focused on advancing RNA-targeted therapies.
Arrakis Therapeutics's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Arrakis Therapeutics has 13 investors. Key investors include Pfizer, ARE, WuXi AppTec, Celgene, and Canaan.
Arrakis Therapeutics operates through Arrakis Therapeutics, Inc.